133 related articles for article (PubMed ID: 31020985)
21. The anticancer properties and mechanism of action of tablysin-15, the RGD-containing disintegrin, in breast cancer cells.
Deng Z; Chai J; Zeng Q; Zhang B; Ye T; Chen X; Xu X
Int J Biol Macromol; 2019 May; 129():1155-1167. PubMed ID: 30660566
[TBL] [Abstract][Full Text] [Related]
22. Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin α
Raposo Moreira Dias A; Pina A; Dal Corso A; Arosio D; Belvisi L; Pignataro L; Caruso M; Gennari C
Chemistry; 2017 Oct; 23(58):14410-14415. PubMed ID: 28816404
[TBL] [Abstract][Full Text] [Related]
23. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.
Almaliti J; Miller B; Pietraszkiewicz H; Glukhov E; Naman CB; Kline T; Hanson J; Li X; Zhou S; Valeriote FA; Gerwick WH
Eur J Med Chem; 2019 Jan; 161():416-432. PubMed ID: 30384045
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of novel peptides through Ugi-ligation and their anti-cancer activities.
Tahoori F; Sheikhnejad R; Balalaie S; Sadjadi M
Amino Acids; 2013 Oct; 45(4):975-81. PubMed ID: 23864432
[TBL] [Abstract][Full Text] [Related]
25. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
Choi Y; Kim E; Lee Y; Han MH; Kang IC
Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
[TBL] [Abstract][Full Text] [Related]
26. Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides.
Zamora A; Gandioso A; Massaguer A; Buenestado S; Calvis C; Hernández JL; Mitjans F; Rodríguez V; Ruiz J; Marchán V
ChemMedChem; 2018 Sep; 13(17):1755-1762. PubMed ID: 29932312
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of peptide-NSAID conjugates for targeted cancer therapy.
Shokri B; Zarghi A; Shahhoseini S; Mohammadi R; Kobarfard F
Arch Pharm (Weinheim); 2019 Aug; 352(8):e1800379. PubMed ID: 31318093
[TBL] [Abstract][Full Text] [Related]
28. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
29. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
30. Bridging disulfides for stable and defined antibody drug conjugates.
Badescu G; Bryant P; Bird M; Henseleit K; Swierkosz J; Parekh V; Tommasi R; Pawlisz E; Jurlewicz K; Farys M; Camper N; Sheng X; Fisher M; Grygorash R; Kyle A; Abhilash A; Frigerio M; Edwards J; Godwin A
Bioconjug Chem; 2014 Jun; 25(6):1124-36. PubMed ID: 24791606
[TBL] [Abstract][Full Text] [Related]
31. Enhancing anticancer treatment: Development of cRGD-Conjugated F-OH-Evo prodrugs for targeted delivery.
Bai H; Huang W; Li J; Ji Y; He S; Hu H
Bioorg Med Chem; 2024 Jun; 107():117759. PubMed ID: 38795572
[TBL] [Abstract][Full Text] [Related]
32. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
33. New Thyrointegrin α
Hay BA; Godugu K; Darwish NHE; Fujioka K; Sudha T; Karakus OO; Mousa SA
J Med Chem; 2021 May; 64(9):6300-6309. PubMed ID: 33886292
[TBL] [Abstract][Full Text] [Related]
34. Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics.
Charoenpattarapreeda J; Walsh SJ; Carroll JS; Spring DR
Angew Chem Int Ed Engl; 2020 Dec; 59(51):23045-23050. PubMed ID: 32894646
[TBL] [Abstract][Full Text] [Related]
35. Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists.
Panzeri S; Zanella S; Arosio D; Vahdati L; Dal Corso A; Pignataro L; Paolillo M; Schinelli S; Belvisi L; Gennari C; Piarulli U
Chemistry; 2015 Apr; 21(16):6265-71. PubMed ID: 25761230
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.
Merlino F; Daniele S; La Pietra V; Di Maro S; Di Leva FS; Brancaccio D; Tomassi S; Giuntini S; Cerofolini L; Fragai M; Luchinat C; Reichart F; Cavallini C; Costa B; Piccarducci R; Taliani S; Da Settimo F; Martini C; Kessler H; Novellino E; Marinelli L
J Med Chem; 2018 Jun; 61(11):4791-4809. PubMed ID: 29775303
[TBL] [Abstract][Full Text] [Related]
37. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
38. Specific Cytostatic and Cytotoxic Effect of Dihydrochelerythrine in Glioblastoma Cells: Role of NF-κB/β-catenin and STAT3/IL-6 Pathways.
Silva TCC; de Faria Lopes GP; de J Menezes-Filho N; de Oliveira DM; Pereira E; Pitanga BPS; Dos Santos Costa R; da Silva Velozo E; Freire SM; Clarêncio J; Borges HL; Rehen SK; Moura-Neto V; Costa SL
Anticancer Agents Med Chem; 2018; 18(10):1386-1393. PubMed ID: 29651966
[TBL] [Abstract][Full Text] [Related]
39. Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates.
Anselmi M; Borbély A; Figueras E; Michalek C; Kemker I; Gentilucci L; Sewald N
Chemistry; 2021 Jan; 27(3):1015-1022. PubMed ID: 32955139
[TBL] [Abstract][Full Text] [Related]
40. Aromatic oligopeptides with chlorambucil moiety--synthesis and biological evaluation.
Bartulewicz D
Acta Pol Pharm; 2005; 62(6):451-5. PubMed ID: 16583984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
